DGAP-News: Apricus Biosciences' CEO to Present at Jefferies 2011 Global Healthcare Conference

(firmenpresse) - Apricus Biosciences, Inc.

26.05.2011 19:32
---------------------------------------------------------------------------

SAN DIEGO, 2011-05-26 19:32 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Bassam Damaj, Ph.D., Chairman,
President and Chief Executive Officer of Apricus Bio, will present at the
Jefferies 2011 Global Healthcare Conference, being held at the Grand Hyatt
Hotel in New York City. The presentation will take place at 11:30am ET on
Thursday, June 9, 2011.

The Company's presentation will be webcast and accessible to the public online
at http://www.wsw.com/webcast/jeff60/apri/ or via the Company's web site at
http://www.apricusbio.com. A replay will be available for 90 days after the
presentation.

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for


information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further development products and
product candidates, have such products and product candidates approved by
relevant regulatory authorities, to successfully commercialize such products
and product candidates and to achieve its other development, commercialization
and financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.


CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development&Investor Relations
Apricus Biosciences, Inc.
(858) 848-4249
ecox@apricusbio.com

Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX



26.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Apricus Biosciences, Inc.


United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
Datum: 26.05.2011 - 19:32 Uhr
Sprache: Deutsch
News-ID 414201
Anzahl Zeichen: 5085

Kontakt-Informationen:

Kategorie:

Wirtschaft (allg.)

Diese Pressemitteilung wurde bisher 306 mal aufgerufen.

DGAP-News: Apricus Biosciences vor Ubernahme des umsatzstarksten Vertriebs- und Marketingunternehmens fur Medikamente in Frankreich ...
Apricus Biosciences, Inc. 21.06.2012 22:44 --------------------------------------------------------------------------- Ubernahme von Finesco-Scomedica ermoglicht Apricus Bio die direkte Einfuhrung von Vitaros(R) und anderen Produkten in Frankreich, dem zweitgrossten Markt fur

DGAP-News: Apricus Biosciences Announces Appointment of Paul V. Maier to Its Board of Directors ...
Apricus Biosciences, Inc. 04.06.2012 15:39 --------------------------------------------------------------------------- SAN DIEGO, 2012-06-04 15:39 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) (www.apricusbio.com) today announced that Paul V. Maier, Ch

DGAP-News: Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances ...
Apricus Biosciences, Inc. 25.05.2012 19:20 --------------------------------------------------------------------------- SAN DIEGO, 2012-05-25 19:20 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com), ann

Weitere Mitteilungen von Apricus Biosciences, Inc.

DGAP-News: Hospital de Denia erhaelt mit Unterstuetzung von Cerner europaeische Auszeichnung fuer IT-Nutzung im Gesundheitswesen ...
Cerner Corporation 26.05.2011 19:15 --------------------------------------------------------------------------- LONDON, 2011-05-26 19:14 CEST (GLOBE NEWSWIRE) -- Die Cerner Corporation und das Hospital de Denia, Teil des Gesundheitsunternehmens Marina Salud in Valencia, Spanien, wurden fuer ihr g

DGAP-News: iQ Power AG: Wachstumsfinanzierung in Korea abgeschlossen ...
DGAP-News: iQ Power AG / Schlagwort(e): Sonstiges iQ Power AG: Wachstumsfinanzierung in Korea abgeschlossen 26.05.2011 / 18:00 --------------------------------------------------------------------- Wachstumsfinanzierung in Korea abgeschlossen - iQ Power Asia Inc. schließt Kapitalerhöhungüber

DGAP-News: NASDAQ OMX Group Announces Preliminary Results of Annual Meeting of Stockholders ...
The NASDAQ OMX Group, Inc. 26.05.2011 17:38 --------------------------------------------------------------------------- NEW YORK, 2011-05-26 17:38 CEST (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that NASDAQ OMX's stockholders approved the following proposal

Besser Betreut gewinnt 2011 Red Herring Top 100 Europe Award ...
Berlin, 26.05.2011. Bei der diesjährigen Red Herring Top 100 Europe Preisverleihung am 25. Mai in Amsterdam wurde die Besser Betreut GmbH als eines der erfolgreichsten Technologie-Unternehmen mit dem Red Herring Europe Award 2011 ausgezeichnet. Überzeugt hat die Vermittlung und Beratung von